PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 1, 2024Research and Practice in Thrombosis and Haemostasis8 citationsOpen Access

A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria

View Full Paper
WDWei DuLMLin Mei

Key Points

Key points are not available for this paper at this time.

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH), a rare hematologic disease, is associated with high maternal and fetal mortality rates. Only 1 medication approved for PNH, the complement component 5 inhibitor eculizumab, has published evidence of use during pregnancy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Du et al. (2024) studied this question.

synapsesocial.com/papers/68e6c1b7b6db643587640569https://doi.org/10.1016/j.rpth.2024.102435
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria2021 · 399 citations
  2. 2Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study2022 · 6 citations
  3. 3Paroxysmal Nocturnal Hemoglobinuria and the Risk of Venous Thrombosis: Review and Recommendations for Management of the Pregnant and Nonpregnant Patient2000 · 132 citations
  4. 4Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience2011 · 54 citations
  5. 5Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria2015 · 282 citations